Venous Thromboembolism Treatment Market Size, Share, Growth, Trends, and Global Industry Analysis: By Drug Type (Factor Xa inhibitors, Thrombolytictherapy, Plasminogen activators, Fondaparinux, Dabigatran, Warfarin), By Disease Type (Deep vein thrombosis, Pulmonary Embolism), By Distribution Channel (Hospital pharmacies, Online Pharmacies, Retail pharmacies) Region Forecast 2019-2030

Venous Thromboembolism Treatment Market size was valued at US$ 1.32 billion in 2023 and is poised to grow at a significant CAGR of 9.0% from 2024-2030. Venous thromboembolism is a disease caused by the clotting of blood in the blood vessel which leads to restriction of blood flow within the circulatory system. Venous thromboembolism is classified into pulmonary embolism and deep vein thrombosis. Deep vein thrombosis is mainly occurred due to the clotting of the blood in the deep vein (commonly in the leg). The formed DVT clot breaks off and flows to the lungs known as pulmonary embolism which is a severe complication of deep vein thrombosis (DVT). Venous thromboembolism commonly occurs in aged persons with more than 60 years. People with overweight, persons with thicker blood and the persons suffering from autoimmune disorders such as (lupus, rheumatoid arthritis etc.) or cancer are at higher risk of venous thromboembolism.

Venous thromboembolism can cause chronic complications, such as post-thrombotic syndrome (PTS) or chronic thromboembolic pulmonary hypertension (CTEPH). The symptoms associated with the venous thromboembolism include dilated blood veins in legs and chest, oedema, fever, tachycardia, and dyspnoea. Lower extremities are the most common site for DVT, but other locations affected include the mesenteric, upper extremities, pelvic veins, and cerebral veins. The market is due to rise in prevalence of venous thromboembolism (According to the International Society of Thrombosis and Haemostasis, Inc.(ISTH), approximately 10 Mn cases of venous thromboembolism occur annually). The most commonly adopted strategies by industry players include new product launches with technological innovations, new product approvals, acquisitions & mergers, agreements, and collaborations to capture significant market share.

Key Developments 

• In March 2017, The Apex trial reported that extended use of betrixaban beyond the parenteral prophylaxis with enoxaparin reduces the venous thromboembolism incidence among the patients.
• In May 2011, Eliquis (apixaban) Approved In Europe for preventing venous thromboembolism after elective knee or hip replacement.
• In January 2015, Bayer  forms the collaboration with academic and governmental institutions for Rivaroxaban study in patients with a recent embolic stroke of undetermined source.